Optimal biological dose: a systematic review in cancer phase I clinical trials

by J. Fraisse, D. Dinart, D. Tosi, C. Bellera, C. Mollevi
Published 2021-01-01

Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5...

by B. Cuer, C. Mollevi, A. Anota, E. Charton, B. Juzyna, T. Conroy, C. Touraine
Published 2020-09-01

GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials

by D. Dinart, J. Fraisse, D. Tosi, A. Mauguen, C. Touraine, S. Gourgou, M. C. Le Deley, C. Bellera, C. Mollevi
Published 2020-06-01

Antibody targeting of claudin-1 as a potential colorectal cancer therapy

by S. Cherradi, A. Ayrolles-Torro, N. Vezzo-Vié, N. Gueguinou, V. Denis, E. Combes, F. Boissière, M. Busson, L. Canterel-Thouennon, C. Mollevi, M. Pugnière, F. Bibeau, M. Ychou, P. Martineau, C. Gongora, M. Del Rio
Published 2017-06-01